M&A Deal Summary |
|
|---|---|
| Date | 2010-08-02 |
| Target | IDUN Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Conatus Pharmaceuticals |
| Sellers(s) | Pfizer |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2005 |
| Sector | Life Science |
| Employees | 30 |
| Revenue | 22M USD (2019) |
Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus Pharmaceuticals was founded in 2005 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2010 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 81,000 |
| Revenue | 63.6B USD (2024) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 19 |
| Sector: Life Science M&A | 4 of 14 |
| Type: Divestiture M&A Deals | 7 of 15 |
| State: California M&A | 1 of 2 |
| Country: United States M&A | 4 of 13 |
| Year: 2010 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-01-12 |
Pfizer - Veterinary Products
Australia Virbac will acquire rights to a portfolio of livestock products historically marketed in Australia by Fort Dodge Animal Health for use in farm animals, primarily cattle and sheep. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-06 |
FoldRx Pharmaceuticals
Cambridge, Massachusetts, United States FoldRx Pharmaceuticals is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis). The Company's lead product, FX-4006, has begun a Phase II/III study in familial amyloid polyneuropathy. FoldRx Pharmaceuticals was founded in 2003 and is based in Cambridge, Massachusetts. |
Buy | - |
